These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 18171229)

  • 21. Comparing the effectiveness of efavirenz and nevirapine for first-line antiretroviral therapy in a South African multicentre cohort.
    Bock P; Fatti G; Grimwood A
    Int Health; 2013 Jun; 5(2):132-8. PubMed ID: 24030113
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
    Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
    AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus.
    Macías J; Berenguer J; Japón MA; Girón JA; Rivero A; López-Cortés LF; Moreno A; González-Serrano M; Iribarren JA; Ortega E; Miralles P; Mira JA; Pineda JA
    Hepatology; 2009 Oct; 50(4):1056-63. PubMed ID: 19670415
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The advantages of therapeutic drug monitoring in patients receiving antiretroviral treatment and experiencing medication-related problems.
    Schoenenberger JA; Aragones AM; Cano SM; Puig T; Castello A; Gomez-Arbones X; Porcel JM
    Ther Drug Monit; 2013 Feb; 35(1):71-7. PubMed ID: 23188184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk of liver decompensation among HIV/hepatitis C virus-coinfected individuals with advanced fibrosis: implications for the timing of therapy.
    Macías J; Márquez M; Téllez F; Merino D; Jiménez-Aguilar P; López-Cortés LF; Ortega E; von Wichmann MA; Rivero A; Mancebo M; Santos J; Pérez-Pérez M; Suárez-Lozano I; Romero-Palacios A; Torres-Cornejo A; Pineda JA
    Clin Infect Dis; 2013 Nov; 57(10):1401-8. PubMed ID: 23946224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Progression of liver fibrosis in patients coinfected with hepatitis C virus and human immunodeficiency virus undergoing antiretroviral therapy.
    Pineda JA; Macías J
    J Antimicrob Chemother; 2005 Apr; 55(4):417-9. PubMed ID: 15731202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Resistance profiles after different periods of exposure to a first-line antiretroviral regimen in a Cameroonian cohort of HIV type-1-infected patients.
    Soria A; Porten K; Fampou-Toundji JC; Galli L; Mougnutou R; Buard V; Kfutwah A; Vessière A; Rousset D; Teck R; Calmy A; Ciaffi L; Lazzarin A; Gianotti N
    Antivir Ther; 2009; 14(3):339-47. PubMed ID: 19474468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.
    Paredes R; Puertas MC; Bannister W; Kisic M; Cozzi-Lepri A; Pou C; Bellido R; Betancor G; Bogner J; Gargalianos P; Bánhegyi D; Clotet B; Lundgren J; Menéndez-Arias L; Martinez-Picado J;
    J Infect Dis; 2011 Sep; 204(5):741-52. PubMed ID: 21844300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in HIV-1 reverse transcriptase potentially associated with hypersusceptibility to nonnucleoside reverse-transcriptase inhibitors: effect on response to efavirenz-based therapy in an urban observational cohort.
    Tozzi V; Zaccarelli M; Narciso P; Trotta MP; Ceccherini-Silberstein F; De Longis P; D'Offizi G; Forbici F; D'Arrigo R; Boumis E; Bellagamba R; Bonfigli S; Carvelli C; Antinori A; Perno CF
    J Infect Dis; 2004 May; 189(9):1688-95. PubMed ID: 15116307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: a retrospective repeated liver biopsy analysis.
    Ingiliz P; Valantin MA; Preziosi P; Finzi L; Pais R; Fedchuk L; Dominguez S; Katlama C; Poynard T; Benhamou Y
    J Hepatol; 2012 Jan; 56(1):49-54. PubMed ID: 21781946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: impact of protease inhibitor therapy.
    Benhamou Y; Di Martino V; Bochet M; Colombet G; Thibault V; Liou A; Katlama C; Poynard T;
    Hepatology; 2001 Aug; 34(2):283-7. PubMed ID: 11481613
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The nonnucleoside reverse transcriptase inhibitors efavirenz and nevirapine in the treatment of HIV.
    Sheran M
    HIV Clin Trials; 2005; 6(3):158-68. PubMed ID: 16192249
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efavirenz replacement by immediate full-dose nevirapine is safe in HIV-1-infected patients in Cambodia.
    Laureillard D; Prak N; Fernandez M; Ngeth C; Moeung S; Riel V; Chhneang V; Song S; Quillet C; Piketty C
    HIV Med; 2008 Aug; 9(7):514-8. PubMed ID: 18554312
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reversibility of cirrhosis in HIV/HBV coinfection.
    Mallet VO; Dhalluin-Venier V; Verkarre V; Correas JM; Chaix ML; Viard JP; Pol S
    Antivir Ther; 2007; 12(2):279-83. PubMed ID: 17503671
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.
    Macías J; Berenguer J; Japón MA; Girón-González JA; Rivero A; López-Cortés LF; Moreno A; Márquez M; Iribarren JA; Ortega E; Miralles P; Merchante N; Pineda JA
    Hepatology; 2012 Oct; 56(4):1261-70. PubMed ID: 22508322
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.
    Sterling RK; Wilson MS; Sanyal AJ; Luketic VA; Stravitz RT; Contos MJ; Mills AS; Shiffman ML
    Clin Gastroenterol Hepatol; 2004 May; 2(5):432-9. PubMed ID: 15118983
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unintended Pregnancies Observed With Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation Over 48 Weeks.
    Scarsi KK; Darin KM; Nakalema S; Back DJ; Byakika-Kibwika P; Else LJ; Dilly Penchala S; Buzibye A; Cohn SE; Merry C; Lamorde M
    Clin Infect Dis; 2016 Mar; 62(6):675-682. PubMed ID: 26646680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determinants of nevirapine hypersensitivity and its effect on the association between hepatitis C status and mortality in antiretroviral drug-naive HIV-positive patients.
    Phillips E; Gutiérrez S; Jahnke N; Yip B; Lima VD; Hogg RS; Harrigan PR; Montaner JS
    AIDS; 2007 Jul; 21(12):1561-8. PubMed ID: 17630551
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-hepatitis C virus treatment may prevent the progression of liver fibrosis in non-responder human immunodeficiency virus/hepatitis C virus coinfected patients.
    Sagnelli C; Uberti-Foppa C; Galli L; Pasquale G; Coppola N; Albarello L; Doglioni C; Lazzarin A; Sagnelli E
    Braz J Infect Dis; 2014; 18(2):164-9. PubMed ID: 24650995
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.